<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2015-3-80-85</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-536</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group></article-categories><title-group><article-title>Treatment for Alzheimer's diseases</article-title><trans-title-group xml:lang="ru"><trans-title>Лечение болезни Альцгеймера</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тювина</surname><given-names>Нина Аркадьевна</given-names></name><name name-style="western" xml:lang="en"><surname>Tyuvina</surname><given-names>Nina Arkadyevna</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра психиатрии и наркологии,</p><p>119021, Москва, ул. Россолимо, 11, стр. 9</p></bio><bio xml:lang="en"><p>Department of Psychiatry and Narcology,</p><p>11, Rossolimo St., Build. 9, Moscow 119021</p></bio><email xlink:type="simple">natuvina@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Балабанова</surname><given-names>В. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Balabanova</surname><given-names>V. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра психиатрии и наркологии,</p><p>119021, Москва, ул. Россолимо, 11, стр. 9</p></bio><bio xml:lang="en"><p>Department of Psychiatry and Narcology,</p><p>11, Rossolimo St., Build. 9, Moscow 119021</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>28</day><month>10</month><year>2015</year></pub-date><volume>7</volume><issue>3</issue><fpage>80</fpage><lpage>85</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Tyuvina N.A., Balabanova V.V., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">Тювина Н.А., Балабанова В.В.</copyright-holder><copyright-holder xml:lang="en">Tyuvina N.A., Balabanova V.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/536">https://nnp.ima-press.net/nnp/article/view/536</self-uri><abstract><p>The paper gives an update on the epidemiology, etiology, pathogenesis, prevention, and treatment of Alzheimer's disease (AD). It points out the role of acetylcholine and glutamatergic components of neurotransmission in the pathogenesis of the disease, as well as their interactions, which is important to keep in mind to have a potentiated response to therapy that includes both these components. Different approaches to AD therapy are considered on the basis of the current ideas on the pathogenetic mechanisms of a degenerative process and with regard to the clinical features of the disease (the nature of the psychopathological symptoms of the disease and its stage). Particular emphasis is placed on compensatory therapy for deficient cholinergic and glutamatergic neurotransmission. Whether psychopharmacological agents may be used and psychotherapeutic work with the relatives of patients with AD should be done are also highlighted. Data on the efficiency of replacement therapy for different dementia stages, which promotes a delay in degenerative processes and a definite stabilization of the mental status, are presented.</p></abstract><trans-abstract xml:lang="ru"><p>Представлены современные данные об эпидемиологии, этиологии, патогенезе, профилактике и лечении болезни Альцгеймера (БА). Отмечена роль ацетилхолинового и глутаматергического компонентов нейротрансмиссии в патогенезе болезни, а также их взаимодействия, что важно учитывать для получения потенцированного ответа при проведении терапии, включающей оба эти компонента. Рассмотрены различные подходы к терапии БА на основе современных представлений о патогенетических механизмах дегенеративного процесса и с учетом клинических особенностей развития заболевания (характера психопатологической симптоматики, стадии течения). Особое внимание уделено компенсаторной терапии, направленной на восполнение дефицита холинергической и глутаматергической нейротрансмиссии. Также освещены вопросы, касающиеся возможности применения психoфармакологических препаратов и необходимости психотерапевческой работы с родственниками больных БА. Представлены данные об эффективности заместительной терапии при разных стадиях деменции, которая способствует замедлению дегенеративных процессов и определенной стабилизации психического состояния.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>болезнь Альцгеймера</kwd><kwd>эпидемиология</kwd><kwd>этиология и патогенез</kwd><kwd>терапия</kwd><kwd>ингибиторы ацетилхолинэстеразы</kwd><kwd>акатинол мемантин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>Alzheimer's disease</kwd><kwd>epidemiology</kwd><kwd>etiology and pathogenesis</kwd><kwd>therapy</kwd><kwd>acetylcholinesterase inhibitors</kwd><kwd>akatinol memantine</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Hebert LE, Scherr PA, Beckett LA, et al. Age specific incidence of Alzheimer's disease in a community population. JAMA. 1995 May 3;273(17):1354-9.</mixed-citation><mixed-citation xml:lang="en">Hebert LE, Scherr PA, Beckett LA, et al. Age specific incidence of Alzheimer's disease in a community population. JAMA. 1995 May 3;273(17):1354-9.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Гаврилова СИ, Колыхалов ИВ, Милопольская ИМ и др. Танакан в лечении начальных проявлений церебрально-сосудистой недостаточности. Клиническая геронтология 1995;(4):22-3. [Gavrilova SI, Kolykhalov IV, Milopol'skaya I, et al. Tanakan in the treatment of initial manifestations of cerebrovascular insufficiency. Klinicheskaya gerontologiya. 1995; (4):22-3. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Гаврилова СИ, Колыхалов ИВ, Милопольская ИМ и др. Танакан в лечении начальных проявлений церебрально-сосудистой недостаточности. Клиническая геронтология 1995;(4):22-3. [Gavrilova SI, Kolykhalov IV, Milopol'skaya I, et al. Tanakan in the treatment of initial manifestations of cerebrovascular insufficiency. Klinicheskaya gerontologiya. 1995; (4):22-3. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Rocca WA, Hofman A, Brayne C, et al. Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. The EURODEMPrevalence Research Group. Ann Neurol. 1991 Sep;30(3):381-90.</mixed-citation><mixed-citation xml:lang="en">Rocca WA, Hofman A, Brayne C, et al. Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. The EURODEMPrevalence Research Group. Ann Neurol. 1991 Sep;30(3):381-90.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. Review. J Neurol Sci. 2007 Jun 15;257(1-2):80-7. Epub 2007 Feb 26.</mixed-citation><mixed-citation xml:lang="en">Jellinger KA, Attems J. Neuropathological evaluation of mixed dementia. Review. J Neurol Sci. 2007 Jun 15;257(1-2):80-7. Epub 2007 Feb 26.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Штернберг ЭЯ. Клиника деменций пресенильного возраста. Москва: Медицина; 1967. 247с. [Shternberg EYa. Klinika dementsii presenil'nogo vozrasta [Clinic of dementia in presenile age]. Moscow: Meditsina; 1967. 247s.]</mixed-citation><mixed-citation xml:lang="en">Штернберг ЭЯ. Клиника деменций пресенильного возраста. Москва: Медицина; 1967. 247с. [Shternberg EYa. Klinika dementsii presenil'nogo vozrasta [Clinic of dementia in presenile age]. Moscow: Meditsina; 1967. 247s.]</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Wang GD, Lai DJ, Burau KD, Du XL. Potential gains in life expectancy from reducing heart disease, cancer, Alzheimer's disease or HIV/AIDS a major causes of death in the USA. Public Health. 2013 Apr;127(4):348-56. doi: 10.1016/j.puhe.2013.01.005. Epub 2013 Mar 16.</mixed-citation><mixed-citation xml:lang="en">Wang GD, Lai DJ, Burau KD, Du XL. Potential gains in life expectancy from reducing heart disease, cancer, Alzheimer's disease or HIV/AIDS a major causes of death in the USA. Public Health. 2013 Apr;127(4):348-56. doi: 10.1016/j.puhe.2013.01.005. Epub 2013 Mar 16.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Selkoe DJ. Defining molecular targets to prevent Alzheimer's disease. Arch Neurol. 2005 Feb;62(2):192-5.</mixed-citation><mixed-citation xml:lang="en">Selkoe DJ. Defining molecular targets to prevent Alzheimer's disease. Arch Neurol. 2005 Feb;62(2):192-5.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Парфенов ВА. Профилактика болезни Альцгеймера. Неврология, нейропсихиатрия, психосоматика. 2011;3(3):8-13. [Parfenov VA. Prevention of Alzheimer's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(3):8-13. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2011-159</mixed-citation><mixed-citation xml:lang="en">Парфенов ВА. Профилактика болезни Альцгеймера. Неврология, нейропсихиатрия, психосоматика. 2011;3(3):8-13. [Parfenov VA. Prevention of Alzheimer's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2011;3(3):8-13. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2011-159</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kalaria RN, Akinyemi R, Ihara M. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci. 2012 Nov 15;322 (1-2):141-7. doi: 10.1016/j.jns.2012.07.032. Epub 2012 Aug 11.</mixed-citation><mixed-citation xml:lang="en">Kalaria RN, Akinyemi R, Ihara M. Does vascular pathology contribute to Alzheimer changes? J Neurol Sci. 2012 Nov 15;322 (1-2):141-7. doi: 10.1016/j.jns.2012.07.032. Epub 2012 Aug 11.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Li G, Rhew IC, Shofer JB, et al. Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study. J Am Geriatr Soc. 2007 Aug;55(8):1161-7.</mixed-citation><mixed-citation xml:lang="en">Li G, Rhew IC, Shofer JB, et al. Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort study. J Am Geriatr Soc. 2007 Aug;55(8):1161-7.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006 Jan;5(1):64-74.</mixed-citation><mixed-citation xml:lang="en">Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006 Jan;5(1):64-74.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev. 2011 May;12(5):e426-37. doi: 10.1111/j.1467-789X.2010.00825.x. Epub 2011 Feb 23.</mixed-citation><mixed-citation xml:lang="en">Anstey KJ, Cherbuin N, Budge M, Young J. Body mass index in midlife and late-life as a risk factor for dementia: a meta-analysis of prospective studies. Obes Rev. 2011 May;12(5):e426-37. doi: 10.1111/j.1467-789X.2010.00825.x. Epub 2011 Feb 23.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ho L, Zhao W, Dams-O'Connor K, et al. Elevated plasma MCP-1 concentration following traumatic brain injury as a potential «predisposition» factor associated with an increased risk for subsequent development of Alzheimer's disease. J Alzheimers Dis. 2012;31(2):301-13. doi: 10.3233/JAD-2012-120598.</mixed-citation><mixed-citation xml:lang="en">Ho L, Zhao W, Dams-O'Connor K, et al. Elevated plasma MCP-1 concentration following traumatic brain injury as a potential «predisposition» factor associated with an increased risk for subsequent development of Alzheimer's disease. J Alzheimers Dis. 2012;31(2):301-13. doi: 10.3233/JAD-2012-120598.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Tan ZS, Vasan RS. Thyroid function and Alzheimer's disease. J Alzheimers Dis. 2009;16(3):503-7. doi: 10.3233/JAD-2009-0991.</mixed-citation><mixed-citation xml:lang="en">Tan ZS, Vasan RS. Thyroid function and Alzheimer's disease. J Alzheimers Dis. 2009;16(3):503-7. doi: 10.3233/JAD-2009-0991.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Wu KY, Hsiao IT, Chen CS, et al. Increased brain amyloid deposition in patients with a lifetime history of major depression: evidence on positron emission tomography. Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):714-22.</mixed-citation><mixed-citation xml:lang="en">Wu KY, Hsiao IT, Chen CS, et al. Increased brain amyloid deposition in patients with a lifetime history of major depression: evidence on positron emission tomography. Eur J Nucl Med Mol Imaging. 2014 Apr;41(4):714-22.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Ptok U, Papassotiropoulos A, Maier W, Heun R. Advanced parental age: a risk factor for Alzheimer's disease or depression in the elderly? Int Psychogeriatr. 2000 Dec;12(4):445-51.</mixed-citation><mixed-citation xml:lang="en">Ptok U, Papassotiropoulos A, Maier W, Heun R. Advanced parental age: a risk factor for Alzheimer's disease or depression in the elderly? Int Psychogeriatr. 2000 Dec;12(4):445-51.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Pardon MC, Rattray I. What do we know about the long-term consequences of stress on ageing and the progression of age-related neurodegenerative disorders? Neurosci Biobehav Rev. 2008 Aug;32(6):1103-20. doi: 10.1016/j.neubiorev.2008.03.005. Epub 2008 Mar 18.</mixed-citation><mixed-citation xml:lang="en">Pardon MC, Rattray I. What do we know about the long-term consequences of stress on ageing and the progression of age-related neurodegenerative disorders? Neurosci Biobehav Rev. 2008 Aug;32(6):1103-20. doi: 10.1016/j.neubiorev.2008.03.005. Epub 2008 Mar 18.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Foster PP, Rosenblatt KP, Kuljis RO. Exercise-induced cognitive plasticity, implications for mild cognitive impairment and Alzheimer's disease. Front Neurol. 2011 May 6;2:28. doi: 10.3389/fneur.2011.00028.eCollection 2011.</mixed-citation><mixed-citation xml:lang="en">Foster PP, Rosenblatt KP, Kuljis RO. Exercise-induced cognitive plasticity, implications for mild cognitive impairment and Alzheimer's disease. Front Neurol. 2011 May 6;2:28. doi: 10.3389/fneur.2011.00028.eCollection 2011.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Paillard T, Rolland Y, de Souto Barreto P. Protective Effects of Physical Exercise in Alzheimer's Disease and Parkinson's Disease: A Narrative Review. J Clin Neurol. 2015 Jul;11(3):212-9. doi: 10.3988/jcn.2015.11.3.212.</mixed-citation><mixed-citation xml:lang="en">Paillard T, Rolland Y, de Souto Barreto P. Protective Effects of Physical Exercise in Alzheimer's Disease and Parkinson's Disease: A Narrative Review. J Clin Neurol. 2015 Jul;11(3):212-9. doi: 10.3988/jcn.2015.11.3.212.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Chakrabarti M, Haque A, Banik NL, et al. Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration. Brain Res Bull. 2014 Oct;109:22-31. doi: 10.1016/j.brainresbull.2014.09.004. Epub 2014 Sep 20.</mixed-citation><mixed-citation xml:lang="en">Chakrabarti M, Haque A, Banik NL, et al. Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration. Brain Res Bull. 2014 Oct;109:22-31. doi: 10.1016/j.brainresbull.2014.09.004. Epub 2014 Sep 20.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Enciu AM, Popescu BO. Is there a causal link between inflammation and dementia? Biomed Res Int. 2013;2013:316495. doi: 10.1155/2013/316495. Epub 2013 Jun 6.</mixed-citation><mixed-citation xml:lang="en">Enciu AM, Popescu BO. Is there a causal link between inflammation and dementia? Biomed Res Int. 2013;2013:316495. doi: 10.1155/2013/316495. Epub 2013 Jun 6.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Cho H, Kim C, Kim HJ, et al. Impact of smoking on neurodegeneration and cerebrovascular disease markers in cognitively normal men. Eur J Neurol. 2015 Aug 11. doi: 10.1111/ene.12816. [Epub ahead of print]</mixed-citation><mixed-citation xml:lang="en">Cho H, Kim C, Kim HJ, et al. Impact of smoking on neurodegeneration and cerebrovascular disease markers in cognitively normal men. Eur J Neurol. 2015 Aug 11. doi: 10.1111/ene.12816. [Epub ahead of print]</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Panza F, Frisardi V, Seripa D, et al. Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective? Review. Int J Geriatr Psychiatry. 2012 Dec;27(12):1218-38. doi: 10.1002/gps.3772. Epub 2012 Mar 7.</mixed-citation><mixed-citation xml:lang="en">Panza F, Frisardi V, Seripa D, et al. Alcohol consumption in mild cognitive impairment and dementia: harmful or neuroprotective? Review. Int J Geriatr Psychiatry. 2012 Dec;27(12):1218-38. doi: 10.1002/gps.3772. Epub 2012 Mar 7.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Solfrizzi V, Panza F, Frisardi V, et al. Diet and Alzheimer's disease risk factors or prevention: the current evidence. Expert Rev Neurother. 2011 May;11(5):677-708. doi: 10.1586/ern.11.56.</mixed-citation><mixed-citation xml:lang="en">Solfrizzi V, Panza F, Frisardi V, et al. Diet and Alzheimer's disease risk factors or prevention: the current evidence. Expert Rev Neurother. 2011 May;11(5):677-708. doi: 10.1586/ern.11.56.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Plassman BL, Breitner JC. Recent advances in the genetics of Alzheimer's disease and vascular dementia with an emphasis on gene-environment interactions. J Am Geriatr Soc. 1996 Oct;44(10):1242-50.</mixed-citation><mixed-citation xml:lang="en">Plassman BL, Breitner JC. Recent advances in the genetics of Alzheimer's disease and vascular dementia with an emphasis on gene-environment interactions. J Am Geriatr Soc. 1996 Oct;44(10):1242-50.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Sleegers K, Van Duijn CM. Alzheimer's disease: genes, pathogenesis and risk prediction. Community Genet. 2001 Jun;4(4):197-203.</mixed-citation><mixed-citation xml:lang="en">Sleegers K, Van Duijn CM. Alzheimer's disease: genes, pathogenesis and risk prediction. Community Genet. 2001 Jun;4(4):197-203.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Wragg M, Hutton M, Talbot C. The Alzheimer's Disease Collaborative Group. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Lancet. 1996 Feb 24;347(9000):509-12.</mixed-citation><mixed-citation xml:lang="en">Wragg M, Hutton M, Talbot C. The Alzheimer's Disease Collaborative Group. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Lancet. 1996 Feb 24;347(9000):509-12.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Bohm C, Chen F, Sevalle J, et al.Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways. Mol Cell Neurosci. 2015;66(Pt A):3-11. doi: 10.1016/j.mcn.2015.02.016. Epub 2015 Mar 4.</mixed-citation><mixed-citation xml:lang="en">Bohm C, Chen F, Sevalle J, et al.Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways. Mol Cell Neurosci. 2015;66(Pt A):3-11. doi: 10.1016/j.mcn.2015.02.016. Epub 2015 Mar 4.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Zekonyte J, Sakai K, Nicoll JA, et al. Quantification of molecular interactions between ApoE, amyloid-beta (Aβ) and laminin: Relevance to accumulation of Aβ in Alzheimer's disease. Biochim Biophys Acta. 2015 Aug 29. pii: S0925-4439(15)00262-8. doi: 10.1016/j.bbadis.2015.08.025. [Epub ahead of print]</mixed-citation><mixed-citation xml:lang="en">Zekonyte J, Sakai K, Nicoll JA, et al. Quantification of molecular interactions between ApoE, amyloid-beta (Aβ) and laminin: Relevance to accumulation of Aβ in Alzheimer's disease. Biochim Biophys Acta. 2015 Aug 29. pii: S0925-4439(15)00262-8. doi: 10.1016/j.bbadis.2015.08.025. [Epub ahead of print]</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Бойко ЕР, Канева АМ. Апопротеин Е и его значение в клинической физиологии. Успехи физиологических наук. 2009;40(1):3-15. [Boiko ER, Kaneva AM. Apoprotein E and its value in clinical physiology. Uspekhi fiziologicheskikh nauk. 2009;40(1):3-15. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Бойко ЕР, Канева АМ. Апопротеин Е и его значение в клинической физиологии. Успехи физиологических наук. 2009;40(1):3-15. [Boiko ER, Kaneva AM. Apoprotein E and its value in clinical physiology. Uspekhi fiziologicheskikh nauk. 2009;40(1):3-15. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Yamaguchi H. Amyloid Morphology and Pathology of Alzheimer's Disease. In: Molecular Biology of Alzheimer's Desease. Genes and Mechanisms Involved in Amyloid Generation. Haas S, editor. Harwood academic publishers;1998. P. 2-14.</mixed-citation><mixed-citation xml:lang="en">Yamaguchi H. Amyloid Morphology and Pathology of Alzheimer's Disease. In: Molecular Biology of Alzheimer's Desease. Genes and Mechanisms Involved in Amyloid Generation. Haas S, editor. Harwood academic publishers;1998. P. 2-14.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Braak H, Braak E. Pattern of cortical lesions in Alzheimer's disease. In Alzheimer's disease: Biology, Diagnosis and Therapeutics. Iqbal K, Winblad B , Nishimura T, Takeda M, Wisniewski HM, editors. England: Wiley; 1997. P. 227-37.</mixed-citation><mixed-citation xml:lang="en">Braak H, Braak E. Pattern of cortical lesions in Alzheimer's disease. In Alzheimer's disease: Biology, Diagnosis and Therapeutics. Iqbal K, Winblad B , Nishimura T, Takeda M, Wisniewski HM, editors. England: Wiley; 1997. P. 227-37.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Yamaguchi H, Hirai S, Morimatsu M, et al. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by β protein immunostain. Acta Neuropathol. 1989;77(3):314-9.</mixed-citation><mixed-citation xml:lang="en">Yamaguchi H, Hirai S, Morimatsu M, et al. Diffuse type of senile plaques in the cerebellum of Alzheimer-type dementia demonstrated by β protein immunostain. Acta Neuropathol. 1989;77(3):314-9.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Wong PC, Savonenko A, Li T, Price DL. Neurobiology of Alzheimer's Disease. In: Basic Neurochemistry, Eighth Edition: Principles of Molecular, Cellular, and Medical Neurobiology. Brady S, Siegel G, Alberts RW, Price D, editors. Amsterdam, London etc.: Academic Press; 2012. P. 815-28.</mixed-citation><mixed-citation xml:lang="en">Wong PC, Savonenko A, Li T, Price DL. Neurobiology of Alzheimer's Disease. In: Basic Neurochemistry, Eighth Edition: Principles of Molecular, Cellular, and Medical Neurobiology. Brady S, Siegel G, Alberts RW, Price D, editors. Amsterdam, London etc.: Academic Press; 2012. P. 815-28.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Selkoe DJ. Alzheimer's Disease. In: Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease (Fifth Edition). Rosenberg RN, Pascual JM, editors. Elsevier; 2015. P. 753-68.</mixed-citation><mixed-citation xml:lang="en">Selkoe DJ. Alzheimer's Disease. In: Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease (Fifth Edition). Rosenberg RN, Pascual JM, editors. Elsevier; 2015. P. 753-68.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Sims NR, Bowen DM, Allen SJ, et al. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem. 1983 Feb;40(2):503-9.</mixed-citation><mixed-citation xml:lang="en">Sims NR, Bowen DM, Allen SJ, et al. Presynaptic cholinergic dysfunction in patients with dementia. J Neurochem. 1983 Feb;40(2):503-9.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Terry AV, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003 Sep;306(3):821-7. Epub 2003 Jun 12.</mixed-citation><mixed-citation xml:lang="en">Terry AV, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther. 2003 Sep;306(3):821-7. Epub 2003 Jun 12.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Selkoe DJ, Landsbury J. Biochemitry of Alzheimer's and prion diseases. In: Basic Neurochemistry. Molecular, Cellular and Medical Asects. 6-th ed. Siegel GJ, Agranoff BW, Alberts RW, Fisher SK, Uhler MD, editors. Philadelphia: Lippincott-Raven; 1999. P. 949-70.</mixed-citation><mixed-citation xml:lang="en">Selkoe DJ, Landsbury J. Biochemitry of Alzheimer's and prion diseases. In: Basic Neurochemistry. Molecular, Cellular and Medical Asects. 6-th ed. Siegel GJ, Agranoff BW, Alberts RW, Fisher SK, Uhler MD, editors. Philadelphia: Lippincott-Raven; 1999. P. 949-70.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Giacobini E. Cholinergic function and Alzheimer's disease. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S1-5.</mixed-citation><mixed-citation xml:lang="en">Giacobini E. Cholinergic function and Alzheimer's disease. Int J Geriatr Psychiatry. 2003 Sep;18(Suppl 1):S1-5.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Shimizu S, Kanetaka H, Hirose D, et al. Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial. Dement Geriatr Cogn Dis Extra. 2015 Apr 10;5(1):135-46. doi: 10.1159/000375527.</mixed-citation><mixed-citation xml:lang="en">Shimizu S, Kanetaka H, Hirose D, et al. Differential effects of acetylcholinesterase inhibitors on clinical responses and cerebral blood flow in patients with Alzheimer's disease: a 12-month, randomized, and open-label trial. Dement Geriatr Cogn Dis Extra. 2015 Apr 10;5(1):135-46. doi: 10.1159/000375527.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotox Res. 2013 Oct;24(3):358-69. doi: 10.1007/s12640-013-9398-z. Epub 2013 May 9.</mixed-citation><mixed-citation xml:lang="en">Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotox Res. 2013 Oct;24(3):358-69. doi: 10.1007/s12640-013-9398-z. Epub 2013 May 9.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Santoro A, Siviero P, Minicuci N, et al. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study. CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.</mixed-citation><mixed-citation xml:lang="en">Santoro A, Siviero P, Minicuci N, et al. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study. CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Bond M, Rogers G, Peters J, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210.</mixed-citation><mixed-citation xml:lang="en">Bond M, Rogers G, Peters J, et al. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Miller LJ. The use of cognitive enhancers in behavioural disturbances of Alzheimer's disease. Consult Pharm. 2007 Sep;22(9):754-62.</mixed-citation><mixed-citation xml:lang="en">Miller LJ. The use of cognitive enhancers in behavioural disturbances of Alzheimer's disease. Consult Pharm. 2007 Sep;22(9):754-62.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593.</mixed-citation><mixed-citation xml:lang="en">Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Гаврилова СИ, Герасимов НП, Калын ЯБ и др. Долговременные эффекты глутаматергической терапии болезни Альцгеймера на стадии умеренно-тяжелой и тяжелой деменции (Результаты 26-недельного сравнительного клинического исследования в параллельных группах больных: леченных акатинолом мемантином и получавших симптоматическую нейролептическую терапию). Социальная и клиническая психиатрия. 2006; 16(1):32-7. [Gavrilova SI, Gerasimov NP, Kalyn YaB i dr. Long-term effects of glutamatergic therapy for Alzheimer's disease at the stage of moderately severe and severe dementia (Results of a 26-week comparative clinical study in parallel groups patients: treated with akatinol memantine and neuroleptic treated with symptomatic therapy). Sotsial'naya i klinicheskaya psikhiatriya. 2006; 16(1):32-7. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Гаврилова СИ, Герасимов НП, Калын ЯБ и др. Долговременные эффекты глутаматергической терапии болезни Альцгеймера на стадии умеренно-тяжелой и тяжелой деменции (Результаты 26-недельного сравнительного клинического исследования в параллельных группах больных: леченных акатинолом мемантином и получавших симптоматическую нейролептическую терапию). Социальная и клиническая психиатрия. 2006; 16(1):32-7. [Gavrilova SI, Gerasimov NP, Kalyn YaB i dr. Long-term effects of glutamatergic therapy for Alzheimer's disease at the stage of moderately severe and severe dementia (Results of a 26-week comparative clinical study in parallel groups patients: treated with akatinol memantine and neuroleptic treated with symptomatic therapy). Sotsial'naya i klinicheskaya psikhiatriya. 2006; 16(1):32-7. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Grossberg GT, Manes F, Allegri RF, et al.The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs. 2013 Jun;27(6):469-78. doi: 10.1007/s40263-013-0077-7.</mixed-citation><mixed-citation xml:lang="en">Grossberg GT, Manes F, Allegri RF, et al.The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs. 2013 Jun;27(6):469-78. doi: 10.1007/s40263-013-0077-7.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin Pharmacokinet. 2013 Apr;52(4):225-41. doi: 10.1007/s40262-013-0038-9.</mixed-citation><mixed-citation xml:lang="en">Noetzli M, Eap CB. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease. Clin Pharmacokinet. 2013 Apr;52(4):225-41. doi: 10.1007/s40262-013-0038-9.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Вознесенская ТГ. Акатинол в лечении некогнитивных нервно-психических расстройств при нейрогериатрических заболеваниях. Неврология, нейропсихиатрия, психосоматика. 2012;4(Спецвыпуск 2):11-7. [Voznesenskaya TG. Akatinol in the treatment of noncognitive neuropsychological disorders in neurogeriatric diseases. Nevrologiya, Neiropsikhiatriya, Psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;4(S2):11-7. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2012-2503</mixed-citation><mixed-citation xml:lang="en">Вознесенская ТГ. Акатинол в лечении некогнитивных нервно-психических расстройств при нейрогериатрических заболеваниях. Неврология, нейропсихиатрия, психосоматика. 2012;4(Спецвыпуск 2):11-7. [Voznesenskaya TG. Akatinol in the treatment of noncognitive neuropsychological disorders in neurogeriatric diseases. Nevrologiya, Neiropsikhiatriya, Psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2012;4(S2):11-7. (In Russ.)]. DOI: http://dx.doi.org/10.14412/2074-2711-2012-2503</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Reisberg B, Doody R, Stö ffler A, et al. Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 3;348(14):1333-41.</mixed-citation><mixed-citation xml:lang="en">Reisberg B, Doody R, Stö ffler A, et al. Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 3;348(14):1333-41.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Вознесенская ТГ, Медведева АВ, Яхно НН. Некогнитивные нейропсихические расстройства при болезни Альцгеймера и их коррекция. Неврологический журнал. 2010;15(4):18-25. [Voznesenskaya TG, Medvedeva AV, Yakhno NN. Non-cognitive neuropsychiatric disorders in Alzheimer's disease and their correction. Nevrologicheskii zhurnal. 2010;15(4):18-25. (In Russ.)].</mixed-citation><mixed-citation xml:lang="en">Вознесенская ТГ, Медведева АВ, Яхно НН. Некогнитивные нейропсихические расстройства при болезни Альцгеймера и их коррекция. Неврологический журнал. 2010;15(4):18-25. [Voznesenskaya TG, Medvedeva AV, Yakhno NN. Non-cognitive neuropsychiatric disorders in Alzheimer's disease and their correction. Nevrologicheskii zhurnal. 2010;15(4):18-25. (In Russ.)].</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Maidment ID, Fox CG, Boustani M, et al. Efficacy of memantine on behavioural and psychological symptoms related to dementia – a systematic meta-analyses. Ann Pharmacother. 2008 Jan;42(1):32-8. Epub 2007 Dec 4.</mixed-citation><mixed-citation xml:lang="en">Maidment ID, Fox CG, Boustani M, et al. Efficacy of memantine on behavioural and psychological symptoms related to dementia – a systematic meta-analyses. Ann Pharmacother. 2008 Jan;42(1):32-8. Epub 2007 Dec 4.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe AD by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008 May;23(5):537-45.</mixed-citation><mixed-citation xml:lang="en">Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe AD by memantine: a pooled data analysis. Int J Geriatr Psychiatry. 2008 May;23(5):537-45.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Wilcock GK, Ballard CG, Cooper JA, et al. Memantine for agitation/aggression and psychosis in moderate severe AD: a pooled analysis of 3 studies. J Clin Psychiatry. 2008 Mar;69(3):341-8.</mixed-citation><mixed-citation xml:lang="en">Wilcock GK, Ballard CG, Cooper JA, et al. Memantine for agitation/aggression and psychosis in moderate severe AD: a pooled analysis of 3 studies. J Clin Psychiatry. 2008 Mar;69(3):341-8.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009 Jun;80(6):600-7. doi: 10.1136/jnnp.2008.158964. Epub 2009 Feb 9.</mixed-citation><mixed-citation xml:lang="en">Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009 Jun;80(6):600-7. doi: 10.1136/jnnp.2008.158964. Epub 2009 Feb 9.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Rammes G, Danysz W, Parsons CG. Pharmacodynamics of Memantine: An Update. Curr Neuropharmacol. 2008 Mar;6(1):55-78. doi: 10.2174/157015908783769671.</mixed-citation><mixed-citation xml:lang="en">Rammes G, Danysz W, Parsons CG. Pharmacodynamics of Memantine: An Update. Curr Neuropharmacol. 2008 Mar;6(1):55-78. doi: 10.2174/157015908783769671.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Fan P. Effects of antidepressants on the inward current mediated by 5-HT3 receptors in rat nodose ganglion neurones. Br J Pharmacol. 1994 Jul;112(3):741-4.</mixed-citation><mixed-citation xml:lang="en">Fan P. Effects of antidepressants on the inward current mediated by 5-HT3 receptors in rat nodose ganglion neurones. Br J Pharmacol. 1994 Jul;112(3):741-4.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Rammes G, Eisensamer B, Ferrari U, et al. Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Mol Psychiatry. 2004 Sep;9(9):846-58, 818.</mixed-citation><mixed-citation xml:lang="en">Rammes G, Eisensamer B, Ferrari U, et al. Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Mol Psychiatry. 2004 Sep;9(9):846-58, 818.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;24(2):138-45. Epub 2007 Jul 4.</mixed-citation><mixed-citation xml:lang="en">Wilkinson D, Andersen HF. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2007;24(2):138-45. Epub 2007 Jul 4.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Gideons ES, Kavalali ET, Monteggia LM. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci USA. 2014 Jun 10;111(23):8649-54. doi: 10.1073/pnas.1323920111. Epub 2014 May 27.</mixed-citation><mixed-citation xml:lang="en">Gideons ES, Kavalali ET, Monteggia LM. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci USA. 2014 Jun 10;111(23):8649-54. doi: 10.1073/pnas.1323920111. Epub 2014 May 27.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Hagan RM, Kilpatrick GJ, Tyers MB. Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse. Psychopharmacology (Berl). 1993;112(1 Suppl):S68-75.</mixed-citation><mixed-citation xml:lang="en">Hagan RM, Kilpatrick GJ, Tyers MB. Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse. Psychopharmacology (Berl). 1993;112(1 Suppl):S68-75.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Annweiler C, Herrmann FR, Fantino B, et al. Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. Cogn Behav Neurol. 2012 Sep;25(3):121-7. doi: 10.1097/WNN.0b013e31826df647.</mixed-citation><mixed-citation xml:lang="en">Annweiler C, Herrmann FR, Fantino B, et al. Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. Cogn Behav Neurol. 2012 Sep;25(3):121-7. doi: 10.1097/WNN.0b013e31826df647.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Chow TW, Pollock BG, Milgram NW. Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease. Neuropsychiatr Dis Treat. 2007;3(5):627-36.</mixed-citation><mixed-citation xml:lang="en">Chow TW, Pollock BG, Milgram NW. Potential cognitive enhancing and disease modification effects of SSRIs for Alzheimer's disease. Neuropsychiatr Dis Treat. 2007;3(5):627-36.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Pinna G, Costa E, Guidotti A. SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Curr Opin Pharmacol. 2009 Feb;9(1):24-30. doi: 10.1016/j.coph.2008.12.006. Epub 2009 Jan 20.</mixed-citation><mixed-citation xml:lang="en">Pinna G, Costa E, Guidotti A. SSRIs act as selective brain steroidogenic stimulants (SBSSs) at low doses that are inactive on 5-HT reuptake. Curr Opin Pharmacol. 2009 Feb;9(1):24-30. doi: 10.1016/j.coph.2008.12.006. Epub 2009 Jan 20.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Bassil N, Thaipisuttikul P, Grossberg GT. Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease. Expert Opin Pharmacother. 2010 Jul;11(10):1765-71. doi: 10.1517/14656566.2010.493874.</mixed-citation><mixed-citation xml:lang="en">Bassil N, Thaipisuttikul P, Grossberg GT. Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease. Expert Opin Pharmacother. 2010 Jul;11(10):1765-71. doi: 10.1517/14656566.2010.493874.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Shao ZQ. Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer's disease. Int J Clin Exp Med. 2015 Feb 15;8(2):2944-8. eCollection 2015.</mixed-citation><mixed-citation xml:lang="en">Shao ZQ. Comparison of the efficacy of four cholinesterase inhibitors in combination with memantine for the treatment of Alzheimer's disease. Int J Clin Exp Med. 2015 Feb 15;8(2):2944-8. eCollection 2015.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Touchon J, Lachaine J, Beauchemin C, et al. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France. Eur J Health Econ. 2014 Nov;15(8):791-800. doi: 10.1007/s10198-013-0523-y. Epub 2013 Aug 9.</mixed-citation><mixed-citation xml:lang="en">Touchon J, Lachaine J, Beauchemin C, et al. The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer's disease to nursing homes: cost-effectiveness analysis in France. Eur J Health Econ. 2014 Nov;15(8):791-800. doi: 10.1007/s10198-013-0523-y. Epub 2013 Aug 9.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
